{"id":15628,"date":"2022-11-23T08:54:24","date_gmt":"2022-11-23T07:54:24","guid":{"rendered":"https:\/\/ggba.swiss\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/"},"modified":"2023-07-04T13:40:44","modified_gmt":"2023-07-04T11:40:44","slug":"geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/","title":{"rendered":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million"},"content":{"rendered":"\n

ObsEva<\/a>\u00a0is a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health and pregnancy. The company candidate,\u00a0ebopiprant<\/a>, is an investigational, orally active, selective prostaglandin receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.<\/p>\n

Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. The Geneva-based company has recently announced the sale of all of the company\u2019s rights to Ebopiprant to XOMA Corporation<\/a>.<\/p>\n

\u201cThe sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,\u201d\u00a0said Brian O\u2019Callaghan, CEO of ObsEva. \u201cThe transaction marks the successful completion of a restructuring process whereby we have extracted material savings through the assignment of contracts, streamlined our organizational structure, and restructured our debt. With the receipt of the upfront payment, we expect to have more than a year of cash runway and an enhanced strategic position, and we intend to turn the company\u2019s resources towards nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization, while also evaluating strategic options to maximize shareholder value. ObsEva retains worldwide, exclusive, commercial rights for nolasiban, except for the People\u2019s Republic of China.\u201d<\/p>\n

In addition to the USD 15 million received in upfront proceeds, ObsEva is eligible to receive up to USD 98 million upon the achievement of certain development and regulatory milestones and sales milestones under the company\u2019s license agreement with Organon for Ebopiprant that was sold to XOMA in the transaction. In July 2021, ObsEva granted a license to Organon<\/a> for the global development, manufacturing, and commercial rights to Ebopiprant.<\/p>\n","protected":false},"excerpt":{"rendered":"

Women’s and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma for up to USD 113 million.<\/p>\n","protected":false},"author":3,"featured_media":15629,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,902,911],"class_list":["post-15628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-personalized-medicine","tag-pharma"],"acf":[],"yoast_head":"\nGeneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Women's and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma for up to USD 113 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-23T07:54:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:40:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million\",\"datePublished\":\"2022-11-23T07:54:24+00:00\",\"dateModified\":\"2023-07-04T11:40:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\"},\"wordCount\":315,\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg\",\"keywords\":[\"Biotech\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\",\"name\":\"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg\",\"datePublished\":\"2022-11-23T07:54:24+00:00\",\"dateModified\":\"2023-07-04T11:40:44+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/","og_locale":"en_US","og_type":"article","og_title":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area","og_description":"Women's and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma for up to USD 113 million.","og_url":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2022-11-23T07:54:24+00:00","article_modified_time":"2023-07-04T11:40:44+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#article","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million","datePublished":"2022-11-23T07:54:24+00:00","dateModified":"2023-07-04T11:40:44+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/"},"wordCount":315,"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg","keywords":["Biotech","Personalized Medicine","Pharma"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/","url":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/","name":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage"},"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg","datePublished":"2022-11-23T07:54:24+00:00","dateModified":"2023-07-04T11:40:44+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-3.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-biopharma-obseva-sells-its-ebopiprant-license-for-up-to-usd-113-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/en\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=15628"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15628\/revisions"}],"predecessor-version":[{"id":17278,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15628\/revisions\/17278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/15629"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=15628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=15628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=15628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}